CARB-X funds VenatoRx Pharmaceuticals to support the development of a new class of oral antibiotics to treat multi-drug-resistant gonorrhea
Funding represents 51st CARB-X Award, and 2nd CARB-X Award for VenatoRx 

See more here


Palvella Therapeutics Commences Phase 3 Portion of Phase 2/3 Pivotal Study of PTX-022 in Pachyonychia Congenita
Fast Track-designated program aims to be first targeted therapy addressing root cause of chronically debilitating rare genetic disease 

See more here


Tmunity and Oncora Medical Partner to Advance the Use of Real-World Data to Accelerate the Availability of CAR-T Therapies for Cancer Patients
– Strategic collaboration may support future trials with CAR T-cell therapy 
– Tmunity will use Oncora Medical’s proprietary analytical tools to access real world data and innovate clinical trial design

See more here


pH Pharma and Immunome Enter into Collaboration and License Agreement to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates in Oncology

See more here


Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression

Findings show that REL-1017 has rapid onset and sustained antidepressant efficacy with statistically significant differences compared to placebo on all efficacy measures

See more here


Mebias Discovery Raises $3.5 Million to Expand Pipeline Using a Novel, Cell Signaling-Pathway Selective GPCR Drug Discovery Platform

Developing Programs to Focus on GI and Inflammation Therapies with Reduced, or No, Side Effects 

See more here


Pillo Health And BLACK+DECKER Partner To Deliver Smart Home Care Companion

See more here


Varian and Oncora Partner to Accelerate Precision Medicine in Radiation Oncology

See more here


VenatoRx Pharmaceuticals Names Joseph C. Larsen, Ph.D. Vice President, Strategic Portfolio Development

See more here